

**Bruce N. Kuhlik**  
SENIOR VICE PRESIDENT  
GENERAL COUNSEL



6151 '04 JUN -1 12:33

June 1, 2004

Division of Dockets Management (HFA-305)  
Food and Drug Administration  
5630 Fishers Lane, Room 1061  
Rockville, MD 20852

Re: Prescription Drug Importation; Docket No. 2004N-0015; 69 Fed. Reg.  
12810 (March 18, 2004)

Dear Sir/Madam:

The Pharmaceutical Research and Manufacturers of America (PhRMA) is pleased to submit comments regarding prescription drug importation to the Task Force convened by the Secretary of Health and Human Services in accordance with Section 1122 of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) (Pub. L. No. 108-173). PhRMA represents the country's leading research-based pharmaceutical and biotechnology companies, which are devoted to inventing medicines that allow patients to lead longer, healthier and more productive lives. Investing more than \$30 billion annually in discovering and developing new medicines, PhRMA companies are leading the way in the search for cures.

PhRMA's detailed comments to the importation docket are contained in the attached memorandum and appendix, two copies of which accompany this letter. If you have any questions, please do not hesitate to contact me at the telephone number below or Erika Lietzan at 202/835-3529.

Thank you for your consideration of these comments.

Sincerely,

A handwritten signature in dark ink, appearing to read "Bruce N. Kuhlik".

Bruce N. Kuhlik  
Senior Vice President & General Counsel

2004N-0115

C 11

*Pharmaceutical Research and Manufacturers of America*

1100 Fifteenth Street, NW, Washington, DC 20005 • Tel: 202-835-3469 • FAX: 202-728-3932 • E-MAIL: bkuhlik@phrma.org